Total | Male | Female | P value | ||
Monotherapy | DIU | 83 (3.3%) | 41 (3.5%) | 42 (3.2%) | 0.414 |
CCB | 1835 (73.8%) | 871 (73.5%) | 964 (74.0%) | 0.410 | |
ACEI | 124 (5.0%) | 69 (5.8%) | 55 (4.2%) | 0.041 | |
BB | 150 (6.0%) | 66 (5.6%) | 84 (6.4%) | 0.202 | |
ARB | 272 (10.9%) | 140 (11.8%) | 132 (10.1%) | 0.100 | |
TCM | 162 (6.5%) | 64 (5.4%) | 98 (7.5%) | 0.019 | |
Others | 61 (2.5%) | 29 (2.4%) | 32 (2.5%) | 0.548 | |
Total monotherapy | 2304 (92.6%) | 1096 (92.5%) | 1208 (92.7%) | 0.447 | |
Combination therapy | 184 (7.4%) | 89 (7.5%) | 95 (7.3%) |
ACEI, ACE inhibitors; ARB, angiotensin receptor blockers; BB, beta blockers; CCB, calcium channel blockers; DIU, diuretics; TCM, traditional Chinese medicine.